

Infantile Neuroaxonal Dystrophy - Market Insights, Epidemiology and Market Forecast-2027

<https://marketpublishers.com/r/IB1B912F09EEN.html>

Date: October 2018

Pages: 120

Price: US\$ 6,250.00 (Single User License)

ID: IB1B912F09EEN

Abstracts

This report can be delivered to the clients within 7-10 Business Days

DelveInsight's 'Infantile Neuroaxonal Dystrophy - Market Insights, Epidemiology and Market Forecast-2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Infantile Neuroaxonal Dystrophy in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Infantile Neuroaxonal Dystrophy from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

GEOGRAPHY COVERED

The United States

EU5 (Germany, France, Italy, Spain and the United Kingdom)

Japan

Study Period: 2016-2027

Infantile Neuroaxonal Dystrophy - Disease Understanding and Treatment Algorithm

Infantile Neuroaxonal Dystrophy (INAD) or PLA2G6-Associated Neurodegeneration (PLAN), which is also known as, Neurodegeneration with Brain Iron Accumulation (NBIA) and Seitelberger Disease, is an ultra-rare, devastating life-shortening neurodegenerative disorder that affects only a few hundred patients worldwide. It is caused by a genetic defect in the PLA2G6 housekeeping gene that removes damaged lipids from cells. Many children with INAD do not live beyond age 10, but some do survive into their teens or later ages.

The DelveInsight Infantile Neuroaxonal Dystrophy market report gives the thorough understanding of the Infantile Neuroaxonal Dystrophy by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Infantile Neuroaxonal Dystrophy in the US, Europe, and Japan.

Infantile Neuroaxonal Dystrophy Epidemiology

The Infantile Neuroaxonal Dystrophy epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology scenario of Infantile Neuroaxonal Dystrophy in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.

As per National Institutes of Health (USA), infantile neuroaxonal dystrophy is a very rare disorder. Its specific incidence is unknown. According to Great Ormond Street Hospital for Children NHS Foundation Trust, each pregnancy carries a 25 percent chance of the child being affected.

Infantile Neuroaxonal Dystrophy Drug Chapters

This segment of the Infantile Neuroaxonal Dystrophy report encloses the detailed

analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Although there is no treatment yet available that can stop the disease, drugs are given to treat infections, pain relief and sedative drugs can be given if required, and feeding can be assisted. Oral or intrathecal baclofen can be given to those with atypical Infantile Neuroaxonal Dystrophy who have significant dystonia. Transdermal scopolamine patch can be given to reduce the volume of secretions in those with excessive drooling or difficulty controlling secretions. Because some individuals with PLA2G6-Associated Neurodegeneration (PLAN) have high brain iron and this disorder falls into the category of NBIA, the option of therapies to remove iron (chelation) is sometimes raised.

Infantile Neuroaxonal Dystrophy Market Outlook

The Infantile Neuroaxonal Dystrophy market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

Currently, the pipeline for INAD is not so lucrative as there is only 1 drug, i.e., RT001 (Retrotape). But, the expected launch of RT001 in the future will create a positive impact on the INAD market. US FDA has granted Orphan Drug Designation for RT001 in the treatment of Phospholipase 2G6 (PLA2G6)-Associated Neurodegeneration (PLAN).

Infantile Neuroaxonal Dystrophy Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in

the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Infantile Neuroaxonal Dystrophy Report Insights

Patient Population

Therapeutic Approaches

Pipeline Analysis

Market Size and Trends

Market Opportunities

Impact of upcoming Therapies

Infantile Neuroaxonal Dystrophy Report Key Strengths

10 Years Forecast

7MM Coverage

Epidemiology Segmentation

Sub-type Segmentation

Key Cross Competition

Highly Analyzed Market

Drugs Uptake

Infantile Neuroaxonal Dystrophy Report Assessment

Current Treatment Practices

Unmet Needs

Pipeline Product Profiles

Market Attractiveness

Market Drivers and Barriers

KEY BENEFITS

This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Infantile Neuroaxonal Dystrophy market

Organize sales and marketing efforts by identifying the best opportunities for Infantile Neuroaxonal Dystrophy market

To understand the future market competition in the Infantile Neuroaxonal Dystrophy market.

Contents

1. KEY INSIGHTS

2. INAD: MARKET OVERVIEW AT A GLANCE

2.1. Total Market Share (%) Distribution of Infantile Neuroaxonal Dystrophy (INAD) in 2016

2.2. Total Market Share (%) Distribution of INAD in 2027

3. DISEASE BACKGROUND AND OVERVIEW: INAD

3.1. Introduction

3.2. Signs and Symptoms

3.3. Classification of INAD

3.4. Stages and GRADE

3.5. Pathophysiology

3.6. Genetic Basis of INAD according to Genome-Wide Association Study

3.7. Causes and Risk factors for INAD

3.8. Risk Factors

3.9. Diagnosis

4. EPIDEMIOLOGY AND PATIENT POPULATION

4.1. Key Findings

5. 7MM TOTAL PREVALENT PATIENT POPULATION OF INAD

6. COUNTRY WISE-EPIDEMIOLOGY OF INAD DISEASE

6.1. United States

6.1.1. Assumptions and Rationale

6.1.2. Total Prevalent Population of INAD in the United States

6.1.3. Diagnosed and Treatable cases of INAD in the United States

6.2. EU5 Countries

6.2.1. Assumptions and Rationale

6.2.2. Total Prevalent Population of INAD in the EU5 Countries

6.2.3. Diagnosed and Treatable cases of INAD in the EU5 Countries

6.3. Germany

- 6.3.1. Total Prevalent Population of INAD in the Germany
- 6.3.2. Diagnosed and Treatable cases of INAD in the Germany
- 6.4. France
 - 6.4.1. Total Prevalent Population of INAD in the France
 - 6.4.2. Diagnosed and Treatable cases of INAD in the France
- 6.5. Italy
 - 6.5.1. Total Prevalent Population of INAD in the Italy
 - 6.5.2. Diagnosed and Treatable cases of INAD in the Italy
- 6.6. Spain
 - 6.6.1. Total Prevalent Population of INAD in the Spain
 - 6.6.2. Diagnosed and Treatable cases of INAD in the Spain
- 6.7. United Kingdom
 - 6.7.1. Assumptions and Rationale
 - 6.7.2. Total Prevalent Population of INAD in the United Kingdom
 - 6.7.3. Diagnosed and Treatable cases of INAD in the United Kingdom
- 6.8. Japan
 - 6.8.1. Assumptions and Rationale
 - 6.8.2. Total Prevalent Population of INAD in Japan
 - 6.8.3. Diagnosed and Treatable cases of INAD in the Japan

7. TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES

8. UNMET NEEDS

9. EMERGING DRUGS

- 9.1. Key Cross Competition
- 9.2. RT001: Retrotope
 - 9.2.1. Product Description
 - 9.2.2. Other Developmental Activities
 - 9.2.3. Clinical Development
 - 9.2.4. Safety and Efficacy
 - 9.2.5. Advantages and Disadvantages
 - 9.2.6. Product Profile

Drug list continued..

10. INAD: 7 MAJOR MARKET ANALYSIS

10.1. Key Findings

10.2. Market Size of INAD in 7MM

11. THE UNITED STATES MARKET OUTLOOK

11.1.1. Total Market size of INAD

11.1.2. United States Market Size by Therapy

12. EU-5 COUNTRIES: MARKET OUTLOOK

12.1. Germany

12.1.1. Total Market size of INAD

12.1.2. Germany Market Size by Therapy

12.2. France

12.2.1. Total Market size of INAD

12.2.2. France Market Size by Therapy

12.3. Italy

12.3.1. Total Market size of INAD

12.3.2. Italy Market Size by Therapy

12.4. Spain

12.4.1. Total Market size of INAD

12.4.2. Spain Market Size by Therapy

12.5. United Kingdom

12.5.1. Total Market size of INAD

12.5.2. United Kingdom Market Size by Therapy

13. JAPAN: MARKET OUTLOOK

13.1. Total Market size of INAD

13.2. Japan Market Size by Therapy

14. MARKET DRIVERS

15. MARKET BARRIERS

16. APPENDIX

16.1. Report Methodology

17. DELVEINSIGHT CAPABILITIES

List Of Tables

LIST OF TABLES

- Table 1: Total Prevalent Population of INAD in the 7MM (2016-2027)
- Table 2: Diagnosed and Treatable cases of INAD in the 7MM (2016-2027)
- Table 3: Total Prevalent Population of INAD in the United States (2016-2027)
- Table 5: Diagnosed and Treatable cases of INAD in the US (2016-2027)
- Table 8: Total Prevalent Population of INAD in Germany (2016-2027)
- Table 9: Diagnosed and Treatable cases of INAD in the Germany (2016-2027)
- Table 13: Total Prevalent Population of INAD in France (2016-2027)
- Table 15: Diagnosed and Treatable cases of INAD in France (2016-2027)
- Table 20: Total Diagnosed Prevalent Population of INAD in Italy (2016-2027)
- Table 21: Diagnosed and Treatable cases of INAD in Italy (2016-2027)
- Table 23: Total Prevalent Population of INAD in Spain (2016-2027)
- Table 25: Diagnosed and Treatable cases of INAD in Spain (2016-2027)
- Table 28: Total Prevalent Population of INAD in the UK (2016-2027)
- Table 29: Diagnosed and Treatable cases of INAD in the UK (2016-2027)
- Table 33: Total Prevalent Population of INAD in Japan (2016-2027)
- Table 35: Diagnosed and Treatable cases of INAD in Japan (2016-2027)
- Table 38: Management of INAD
- Table 40: Key recommendations for INAD
- Table 43: Emerging Drugs Analysis (Phase II / III)
- Table 54: 7 Major Market Size of INAD in USD Million (2016-2027)
- Table 55: 7 Major Market Size of INAD by Therapy in USD Million (2016-2027)
- Table 56: Market Size of INAD in United States in USD Million (2016-2027)
- Table 55: United States Market Size of INAD by Therapy in USD Million (2016-2027)
- Table 57: Market Size of INAD in Germany, in USD Million (2016-2027)
- Table 55: Germany Market Size of INAD by Therapy in USD Million (2016-2027)
- Table 58: Market Size of INAD in France, in USD Million (2016-2027)
- Table 55: France Market Size of INAD by Therapy in USD Million (2016-2027)
- Table 59: Market Size of INAD in the Italy, in USD Million (2016-2027)
- Table 55: Italy Market Size of INAD by Therapy in USD Million (2016-2027)

List Of Figures

LIST OF FIGURES

Figure 1: Signs and Symptoms of INAD

Figure 2: Clinical manifestations of INAD

Figure 3: Different forms of INAD

Figure 4: Proposed adaptive pathophysiological pathways in INAD

Figure 5: Potential pathophysiology of INAD integrating clinical, immunological, neurovascular, and molecular characteristics

Figure 6: Schematic view of the factors known to contribute to the molecular mechanisms of INAD

Figure 7: Primary pathogenic targets in INAD with their respective treatment options

Figure 8: Representation of proposed mechanisms for INAD

Figure 9: Differential diagnosis of INAD

Figure 10: Total Prevalent Population of INAD in the 7MM (2016-2027)

Figure 11: Diagnosed and Treatable cases of INAD in the 7MM (2016-2027)

Figure 12: Total Prevalent Population of INAD in the United States (2016-2027)

Figure 13: Diagnosed and Treatable cases of INAD in the United States (2016-2027)

Figure 14: Total Prevalent Population of INAD in Germany (2016-2027)

Figure 22: Diagnosed and Treatable cases of INAD in Germany (2016-2027)

Figure 25: Total Prevalent Population of INAD in France (2016-2027)

Figure 27: Diagnosed and Treatable cases of INAD in France (2016-2027)

Figure 30: Total Prevalent Population of INAD in Italy (2016-2027)

Figure 32: Diagnosed and Treatable cases of INAD in Italy (2016-2027)

Figure 35: Total Prevalent Population of INAD in Spain (2016-2027)

Figure 37: Diagnosed and Treatable cases of INAD in Spain (2016-2027)

Figure 40: Total Prevalent Population of INAD in the UK (2016-2027)

Figure 42: Diagnosed and Treatable cases of INAD in the UK (2016-2027)

Figure 45: Total Prevalent Population of INAD in Japan (2016-2027)

Figure 47: Diagnosed and Treatable cases of INAD in Japan (2016-2027)

Figure 50: Proposed algorithm for treatment of INAD.

Figure 51: Unmet Needs of INAD

Figure 52: 7 Major Market Size of INAD in USD Million (2016-2027)

Figure 53: Market Size of INAD in the United States, USD Millions (2016-2027)

Figure 54: United States Market Size of INAD by Therapy in USD Million (2016-2027)

Figure 55: Market Size of INAD in Germany, USD Millions (2016-2027)

Figure 56: Germany Market Size of INAD by Therapy in USD Million (2016-2027)

Figure 57: Market Size of INAD in France, USD Millions (2016-2027)

Figure 58: France Market Size of INAD by Therapy in USD Million (2016-2027)

Figure 59: Market Size of INAD in the Italy, USD Millions (2016-2027)

Figure 60: Italy Market Size of INAD by Therapy in USD Million (2016-2027)

Figure 61: Market Size of INAD in Spain, USD Millions (2016-2027)

Figure 62: Spain Market Size of INAD by Therapy in USD Million (2016-2027)

I would like to order

Product name: Infantile Neuroaxonal Dystrophy - Market Insights, Epidemiology and Market Forecast-2027

Product link: <https://marketpublishers.com/r/IB1B912F09EEN.html>

Price: US\$ 6,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/IB1B912F09EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

